Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Carboplatin
Drug ID BADD_D00364
Description Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma.[L32253] Early clinical studies of carboplatin were performed in 1982.[A230523] Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.[L32248]
Indications and Usage Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma.[L32253] Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.[L32253]
Marketing Status approved
ATC Code L01XA02
DrugBank ID DB00958
KEGG ID D01363
MeSH ID D016190
PubChem ID 426756
TTD Drug ID D0X7HM
NDC Product Code 0703-4239; 55150-386; 63323-172; 68083-191; 63592-0271; 61703-339; 0703-4244; 0703-4246; 72659-863; 50742-447; 69448-005; 61703-600; 55150-334; 61703-262; 61703-360; 71288-100; 49812-0010; 16729-295; 55150-333; 61703-150; 68083-193; 68554-0084; 68083-190; 68083-192; 53104-7570; 54875-0002; 50742-448; 55150-335; 0703-4248
UNII BG3F62OND5
Synonyms Carboplatin | cis-Diammine(cyclobutanedicarboxylato)platinum II | CBDCA | Paraplatin | Paraplatine | Platinwas | Ribocarbo | Carboplat | Neocarbo | Carbosin | Carbotec | Ercar | JM-8 | JM 8 | JM8 | Nealorin | NSC-241240 | NSC 241240 | NSC241240 | Blastocarb
Chemical Information
Molecular Formula C6H12N2O4Pt
CAS Registry Number 41575-94-4
SMILES C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Injection site mass08.02.03.009; 12.07.03.010---
Injection site pain08.02.03.010; 12.07.03.011---
Injection site reaction08.02.03.014; 12.07.03.015--
Interstitial lung disease10.02.01.033; 22.01.02.0030.001287%-
Intestinal ischaemia07.15.02.001; 24.04.08.0010.000336%-
Intestinal obstruction07.13.01.0020.000392%-
Intestinal perforation07.04.06.0020.000336%-
Jaundice cholestatic09.01.01.0050.000168%-
Lacrimation increased06.08.02.0040.000224%
Large intestine perforation07.04.06.005; 12.02.03.0050.000280%
Laryngeal oedema10.01.05.003; 22.04.02.001; 23.04.01.0050.000783%
Laryngospasm22.04.02.0020.000560%
Leukaemia01.10.03.001; 16.01.03.001--
Leukocytosis01.02.01.0020.000280%
Leukoencephalopathy17.13.02.0030.000392%
Leukopenia01.02.02.0010.003794%-
Lip oedema07.05.04.004; 10.01.05.004; 23.04.01.0060.000862%-
Lip pain07.05.05.0290.000112%
Lip swelling07.05.04.005; 10.01.05.005; 23.04.01.0070.000974%-
Liver function test abnormal13.03.04.030---
Loss of consciousness17.02.04.0040.005809%-
Lung consolidation22.01.02.0100.000448%-
Lung infiltration22.01.02.0040.000336%-
Lymphadenopathy01.09.01.0020.000504%-
Lymphopenia01.02.02.0020.000414%-
Malaise08.01.01.0030.007846%
Mass08.03.05.0030.000224%-
Metastases to liver09.04.02.004; 16.22.02.0010.000672%-
Metastases to spine15.09.03.007; 16.22.02.0070.000112%-
Microangiopathic haemolytic anaemia01.06.02.002; 24.03.02.0190.000112%-
The 8th Page    First    Pre   8 9 10 11 12    Next   Last    Total 21 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene